TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis

Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)

(2011) Sang Hoon Lee   ARCHIVES OF PHARMACAL RESEARCH

Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2

(2011) Jennifer Spratlin   Current Oncology Reports

Ramucirumab (IMC-1121B): a novel attack on angiogenesis

(2010) Jennifer L Spratlin et al.   Future Oncology

Activated Forms of VEGF-C and VEGF-D Provide Improved Vascular Function in Skeletal Muscle

(2009) Andrey Anisimov et al.   CIRCULATION RESEARCH

Transgenic Induction of Vascular Endothelial Growth Factor-C Is Strongly Angiogenic in Mouse Embryos but Leads to Persistent Lymphatic Hyperplasia in Adult Tissues

(2008) Marja Lohela et al.   AMERICAN JOURNAL OF PATHOLOGY

Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis

(2008) Ifat Sher et al.   INTERNATIONAL JOURNAL OF CANCER

An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells

(2008) R. Aesoy et al.   MOLECULAR CANCER RESEARCH

VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis

(2007) A. V. Benest et al.   CARDIOVASCULAR RESEARCH